'Baraclude price' presentation slideshows

Can Entecavir lower the risk of Hepatocellular carcinoma in Hepatitis C patients

https://www.cancercurepharmacy.com/BlogDetails.aspx?Title=Can-Entecavir-lower-the-risk-of-Hepatocellular-carcinoma-in-Hepatitis-C-patients Hepatocellular Carcinoma or HCC is the commonly diagnosed form of liver cancer. It is most likely to occur in people with chronic liver disease such as hepatitis C infection. Hepatitis C virus or HCV is a major contributing factor towards cirrhosis and advanced hepatic fibrosis and increased risk for the development of HCC. The mortality rates of HCV associated HCC remain consistently high as the rates of HCV cirrhosis also increase. The usage of new directly acting anti-viral medications (with a higher rate of virological clearance) has great potential as a cure for HCV infections. While the HCC-HCV correlation is reduced due to such medications such as Entecavir. The patients treated with Entecavir / Baraclude remain at risk of developing HCC, especially in case of patients with cirrhosis and advanced fibrosis.

40 views • 3 slides